Average scores of the five patient-reported outcomes after 1 year of RA treatment used to assign patients with an early and persistent treatment response to a cluster (n=140)
| Clusters | |||
|---|---|---|---|
| PRO scores at year 1 | Concordant to disease activity n=109 (77.9%) | Dominant fatigue n=13 (9.3%) | Dominant pain and fatigue n=18 (12.9%) |
| Pain (0–100) | |||
| mean±SD | 7.3±7.5 | 14.5±8.9 | 45.1±14.6 |
| median (Q1–Q3) | 5 (2–3) | 15 (10–20) | 51 (48–68) |
| Fatigue (0–100) | |||
| mean±SD | 10.0±9.9 | 69.6±14.3 | 42.4±14.0 |
| median (Q1–Q3) | 10 (2–20) | 70 (60–80) | 51 (45–60) |
| Physical functioning (0–3) | |||
| mean±SD | 0.1±0.1 | 0.2±0.3 | 0.3±0.3 |
| median (Q1–Q3) | 0 (0–0.1) | 0.1 (0–0.4) | 0.1 (0–0.5) |
| RA-related quality of life (0–30) | |||
| mean±SD | 3.9±4.9 | 6.2±2.4 | 5.6±5.0 |
| median (Q1–Q3) | 2.9 (1–5) | 7 (4–8) | 3 (2.2–8.1) |
| Sleep quality (0–21) | |||
| mean±SD | 5.0±3.0 | 6.0±1.9 | 5.4±2.6 |
| median (Q1–Q3) | 4 (3–6) | 6 (5–7) | 5 (4–6) |
Higher scores indicate worse pain, worse fatigue, more functional loss, worse health-related quality of life and worse sleep quality. Early and persistent response was defined as a DAS28CRP<2.6 at week 16, sustained between week 16 and week 52. PRO, patient-reported outcome; Q1, quartile 1 (25th percentile); Q3, quartile 3 (75th percentile); RA, rheumatoid arthritis.